These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6875011)

  • 1. The effect of serial dilution of betamethasone-17-valerate on blanching potential and chemical stability.
    Ryatt KS; Cotterill JA; Mehta A
    J Clin Hosp Pharm; 1983 Jun; 8(2):143-5. PubMed ID: 6875011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment.
    Ryatt KS; Feather JW; Mehta A; Dawson JB; Cotterill JA; Swallow R
    Br J Dermatol; 1982 Jul; 107(1):71-6. PubMed ID: 7104209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of some variables affecting the blanching activity of betamethasone 17-valerate cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1980; 160(5):321-7. PubMed ID: 7364141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onset of the vasoconstrictor effect of diflucortolone valerate, betamethasone valerate, and fluocinolone acetonide ointments applied for varying periods under occlusive dressings.
    Szadurski J; Renz F; Gasser D
    Dermatologica; 1976; 153(4):236-42. PubMed ID: 1017533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of betamethasone 17-valerate from extemporaneous dilutions of a proprietary topical cream.
    Magnus AD; Haigh JM; Kanfer I
    Dermatologica; 1981; 163(4):331-7. PubMed ID: 7308554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between in vivo skin blanching and in vitro release rate for betamethasone valerate creams.
    Shah VP; Elkins J; Skelly JP
    J Pharm Sci; 1992 Jan; 81(1):104-6. PubMed ID: 1619561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The stability and blanching efficiency of some Betnelan-V cream dilutions.
    Boonsaner P; Remon JP; De Rudder D
    J Clin Hosp Pharm; 1986 Apr; 11(2):101-6. PubMed ID: 3711358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservative activity in diluted corticosteroid creams.
    Hugo WB; Denyer SP; York HL; Tucker JD
    J Hosp Infect; 1984 Sep; 5(3):329-33. PubMed ID: 6208253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stability and blanching efficiency of betamethasone-17-valerate in emulsifying ointment.
    Kirsch JM; Gibson JR; Darley CR
    Br J Dermatol; 1983 Feb; 108(2):250-1. PubMed ID: 6824582
    [No Abstract]   [Full Text] [Related]  

  • 10. Blanching activities of betamethasone formulations. The effect of dosage form on topical drug availability.
    Smith EW; Meyer E; Haigh JM
    Arzneimittelforschung; 1990 May; 40(5):618-21. PubMed ID: 2383308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chromameter results obtained from corticosteroid-induced skin blanching assay: comparison of visual and chromameter data.
    Schwarb FP; Smith EW; Haigh JM; Surber C
    Eur J Pharm Biopharm; 1999 May; 47(3):261-7. PubMed ID: 10382110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dilution of betamethasone ointment.
    Smith JF; Beveridge EG; Orr NA
    Br J Dermatol; 1983 Feb; 108(2):248-50. PubMed ID: 6824581
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
    Bjerring P
    Skin Pharmacol; 1993; 6(3):187-92. PubMed ID: 8274288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once daily application of diflorasone diacetate ointment compared with betamethasone valerate ointment twice daily in patients with eczematous dermatoses.
    Hersle K; Mobacken H
    J Int Med Res; 1982; 10(6):423-5. PubMed ID: 7152081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect on adrenal axis function of topically applied betamethasone valerate ointment 0.1%.
    Fischer GO
    Australas J Dermatol; 1983 Apr; 24(1):26-32. PubMed ID: 6312951
    [No Abstract]   [Full Text] [Related]  

  • 16. High-performance liquid chromatographic assay of betamethasone 17-valerate and its degradation products.
    Li Wan Po A; Irwin WJ; Yip YW
    J Chromatogr; 1979 Sep; 176(3):399-405. PubMed ID: 546923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and degradation of betamethasone 17-valerate in homogenized living skin equivalent.
    Kubota K; Ademola J; Maibach HI
    Dermatology; 1994; 188(1):13-7. PubMed ID: 8305748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The stability of betamethasone-17-valerate in semi-solid bases.
    Yip YW; Po LW
    J Pharm Pharmacol; 1979 Jun; 31(6):400-2. PubMed ID: 39141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications.
    Woodford R; Haigh JM; Barry BW
    Dermatologica; 1983; 166(3):136-40. PubMed ID: 6852325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic effects of topical application of beclomethasone 17,21-dipropionate: comparative studies with betamethasone 17-valerate ointment and fluocinonide cream.
    Shimao S
    J Dermatol; 1979 Dec; 6(6):383-90. PubMed ID: 396316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.